Pyrazinamide adverse reactions: Difference between revisions
Created page with "__NOTOC__ {{Pyrazinamide }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIK..." |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pyrazinamide }} | {{Pyrazinamide}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{Chetan}} | ||
==Adverse Reactions== | |||
===General=== | |||
[[Fever]], [[porphyria]] and [[dysuria]] have rarely been reported. [[Gout]] (see Precautions). | |||
===Gastrointestinal=== | |||
The principal adverse effect is a hepatic reaction (see Warnings:). Hepatotoxicity appears to be dose related, and may appear at any time during therapy. GI disturbances including [[nausea]], [[vomiting]] and [[anorexia]] have also been reported. | |||
===Hematologic and Lymphatic=== | |||
[[Thrombocytopenia]] and [[sideroblastic anemia]] with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. Adverse effects on blood clotting mechanisms have also been rarely reported. | |||
===Other=== | |||
Mild [[arthralgia]] and [[myalgia]] have been reported frequently. Hypersensitivity reactions including [[rashes]], [[urticaria]], and [[pruritis]] have been reported. [[Fever]], [[acne]], [[photosensitivity]], [[porphyria]], [[dysuria]] and [[interstitial nephritis]] have been reported rarely.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a719ec72-771f-49c9-b93d-9d5f585176a4 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 04:17, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Adverse Reactions
General
Fever, porphyria and dysuria have rarely been reported. Gout (see Precautions).
Gastrointestinal
The principal adverse effect is a hepatic reaction (see Warnings:). Hepatotoxicity appears to be dose related, and may appear at any time during therapy. GI disturbances including nausea, vomiting and anorexia have also been reported.
Hematologic and Lymphatic
Thrombocytopenia and sideroblastic anemia with erythroid hyperplasia, vacuolation of erythrocytes and increased serum iron concentration have occurred rarely with this drug. Adverse effects on blood clotting mechanisms have also been rarely reported.
Other
Mild arthralgia and myalgia have been reported frequently. Hypersensitivity reactions including rashes, urticaria, and pruritis have been reported. Fever, acne, photosensitivity, porphyria, dysuria and interstitial nephritis have been reported rarely.[1]
References
Adapted from the FDA Package Insert.